116 results about "Cannabivarin" patented technology

Described are liquid compositions that contain a desired (e.g., extracted) plant material such as cannabinoid, terpene, terpenoid, or the like, contained, e.g., dissolved, suspended, or emulsified, in the liquid, which contains surfactant; methods of preparing these types of liquid compositions; and methods of processing this type of liquid composition to collect, isolate, concentrate, or purify a desired target material contained in the liquid composition.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The present invention relates to crystalline forms of 6-hydroxy cannabidivarin (6-OH CBDV), methods for their production, and their use in therapy. The crystalline forms are easier to handle than other solid forms, such as glass amorphous material, and will useful in the manufacture of medicaments for the treatment of conditions associated with seizure.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

A fatty acid ester of cannabinoid, wherein the fatty acid is an unsaturated acid, with an ester linkage consisting of an aryloxy oxygen directly bonded to an aromatic ring of the cannabinoid and a carbonyl group attached to the fatty acid unsaturated carbon chain.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

The invention relates to a non-natural cannabinoid synthase comprising at least one amino acid variation as compared to a wild type cannabinoid synthase Δ9-tetrahydrocannabinolic acid synthase (THCAS), comprising three alpha helices (αA, αB and αC) where a disulfide bond is not formed between alpha helix αA and alpha helix αC, wherein the non-natural cannabinoid synthase catalyzes the oxidative cyclization of cannabigerolic acid (CBGA) into a cannabinoid. The invention further relates to a non-natural Δ9-tetrahydrocannabinolic acid synthase (THCAS), a non-natural cannabidiolic acid synthase (CBDAS), and a non-natural cannabichromenic acid synthase (CBCAS) comprising at least one amino acid variation as compared to a wild type THCAS, CBDAS, or CBCAS, respectively, comprising three alpha helices (αA, αB and αC) and wherein a disulfide bond is not formed between alpha helix αA and alpha helix αC. The invention also relates to a nucleic acid, expression construct, and engineered cell for making the non-natural THCAS, CBDAS, and / or CBCAS. Also provided are compositions comprising the non-natural THCAS, CBDAS, and / or CBCAS; isolated non-natural THCAS, CBDAS, and / or CBCAS enzymes; methods of making the isolated enzymes; cell extracts comprising cannabinoids; and methods of making cannabinoids.

Apparatus and methods are provided for dispensing into a liquid a soluble substance, such as a soluble flavoring. The soluble flavoring may include a lime flavoring with citric acid. It may include a cannabinoid. Alternatively, the soluble flavoring may not include citric acid or sugar. A useful application of the subject invention includes a lime flavoring held by a gelatinous elastic lime wedge. The gelatinous lime wedge may be retrieved from a protective covering and acted upon so it mixes the lime flavoring into a beverage, such as when it's inserted into a water or beer bottle or can. Rather than needing to buy and store a perishable natural lime, and cut it up, a gelatinous lime wedge holding soluble lime flavoring may be stored for an extended period of time, and placed in functional contact with water, beer, or other liquid, at time of consumption.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Described are liquid compositions that contain a desired (e.g., extracted) plant material such as cannabinoid, terpene, terpenoid, or the like, contained, e.g., dissolved, suspended, or emulsified, in the liquid, which contains surfactant; methods of preparing these types of liquid compositions; and methods of processing this type of liquid composition to collect, isolate, concentrate, or purify a desired target material contained in the liquid composition.

Described herein are novel oligosaccharides of cannabidiol and other cannabinoids and methods of production and uses thereof. The production method includes contacting cannabidiol with UDP-carbohydrate dependent glycosyltransferases (UGT73A class) to produce a cannabinoid-β-D-glycoside, then contacting the product with a cyclomaltodextrin glucanotransferase and a cyclodextrin to elongate the sugar moiety with (1-4)-α-D-glucopyranoside, thereby producing a mixed 0-a-structure in a recombinant host that has an amphiphilic structure as a surfactant solubilizer and different enzymatic degradability of α- and β-D-glucopyranose residues by amylases and β-glycosidases, thereby allowing targeted drug delivery.

Provided is a powder tea composition which enables a cannabinoid-containing food and beverages having a high tea leaf flavor and being capable of sufficiently enjoying the effect of cannabinoid to be produced. Provided is a powder tea composition in a powder form, including a cannabinoid-containing water-soluble granulated product and a tea leaf-ground product.

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure may broadly provide composition for applying to food comprising a cannabidiol (CBD) having a purity greater than 90% and a tetrahydrocannabinol (THC) having a purity greater than 90% at a ratio of CBD:THC of about 5:1 to about 80:1, for a combined cannabinoid concentration of up to 15 g / L, a pharmaceutically compatible carrier oil, a pharmaceutically compatible emulsifier system, greater than 60% w / v water, and the composition having a viscosity of 500 to 5,000 cP at 21°C, a pH of between 4-7 and being in the form of an oil-in-water nanoemulsion.

This invention provides methods for the synthesis of cannabidiol and its analogues, as well as related compounds, formulations, and methods of use. [Solution] Methods are provided for the synthesis of oliveitol, oliveitol analogs, cannabidiol (CBD), CBD analogs, and other cannabinoids. One method uses phloroglucinol or phloroglucinol analogs as starting materials. The synthesis is stereospecific, efficient, selective, cost-effective, and THC((-)-trans-Δ 9 There is little to no possibility of generating (tetrahydro-cannabinol) or any other psychoactive by-products. Shortened synthesis is also provided, as well as new cannabinoids, pharmaceutical formulations, and methods of use.

A solid cannabinoid composition comprising: (i) 0.3 to 10 wt.% of one or more cannabinoids; (ii) from 4 to 69 wt.% of one or more non-ionic surfactants having an HLB value of from 10 to 25; and (iii) at least 20 wt.% of one or more carbohydrates selected from the group consisting of mannitol, sucrose, trehalose and stachyose; (iv) 0 to 5 wt.% of water; wherein the combination of the one or more non-ionic surfactants and the one or more carbohydrates comprises at least 70 wt.% of the composition. A sterile aqueous liquid for medical treatment, the liquid comprising: (a) 0.1 to 10 mg / mL of one or more cannabinoids; (b) one or more nonionic surfactants having an HLB value of from 10 to 25; (c) one or more carbohydrates selected from the group consisting of mannitol, sucrose, trehalose and stachyose; and (d) at least 85 wt.% water; wherein the one or more nonionic surfactants and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3: 1 to 30: 1, and wherein the one or more carbohydrates and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3: 1 to 300: 1.

A method is provided for producing a bee product infused with one or more target compounds. In one embodiment, the method includes constraining pollen collection by bees to a selection of plants and extracting a plant-derived material from bee hives. The method further includes measuring a content of the one or more target compounds of the cannabinoid-plant-derived material and packaging the plant-derived material based on the content of the one or more target compounds.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and / or an olivetolic acid cyclase (OAC).

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

This invention discloses a quantitative analysis method for tetrahydrocannabinol (THC) and cannabidiol (CBD). The analytical method includes the following steps: injecting the sample into a gas chromatograph, subjecting it to programmed temperature rise, and detecting the total content of CBD and / or THC using an external standard method; wherein the injection port temperature of the gas chromatograph is 200–300°C; the programmed temperature rise is from 150°C to 280°C; and the programmed temperature rise rate is 10–30°C / min. This analytical method can easily and accurately detect the total amount of usable THC and CBD in cannabis flower and leaf raw materials or extracts. Firstly, no special pretreatment of the sample is required; only a certain organic solvent is needed to achieve complete and effective extraction and simple filtration of the cannabinoid components in the sample. Secondly, no THCA and CBDA reference standards are needed to detect the actual total amount of THC and CBD. Thirdly, the quantitative analysis results are accurate and reliable.

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

Various approaches preparing Cannabis flower samples for analysis of cannabinoid content, the method comprising the steps of weighing the sample in a portable or benchtop balance; adding, to a container, the weighed sample and a solvent; agitating the vial and thereafter extracting a liquid component therefrom; and analytically analyzing the sample using the solvent based on the weight and a volume of the extracted liquid.

Provided is a method for treating conditions and / or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and / or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight / weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight / weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.